

CLINICAL INSIGHTS

BLUE CROSS Division of Blue Cross Laboratories

K-MET TABLETS

Issue VII, No.22, 2024

Gout risk in adults with pre-diabetes initiating metformin

Marrugo J et.al; Ann Rheum Dis; 2024

- Individuals with prediabetes not only are at an elevated risk for diabetes but also face an increased risk for incident gout.
- This study assessed the gout-lowering properties of metformin in 25,064 individuals with prediabetes (age ≥ 18 years; <u>A1c</u> levels, 5.7%-6.4%) who had never reported A1c levels > 6.4%.
- Patients who were initiated on metformin within 18 months after the diagnosis of prediabetes (n = 1154) were propensity score-matched with those who did not initiate metformin or other antidiabetic medications in this period (n = 13,877) and were followed for a median of 3.9 years for the primary outcome of incident gout.
- The results were consistent across different subgroups stratified on the basis of sex, age (≤ 60 vs > 60 years), estimated glomerular filtration rate (≥ 90 vs < 90 mL/min/1.73 m²), and baseline diuretic use.

Metformin use was associated with a reduced risk of gout among adults with pre-diabetes.

* * * * * *